ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Safran SA

Safran SA (SAF)

211.60
-3.30
(-1.54%)
Closed January 05 11:30AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
211.60
Bid
211.40
Ask
213.20
Volume
431,385
211.40 Day's Range 214.10
156.68 52 Week Range 228.60
Market Cap
Previous Close
214.90
Open
214.00
Last Trade
386
@
211.6
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
589,286
Shares Outstanding
426,500,891
Dividend Yield
1.04%
PE Ratio
26.20
Earnings Per Share (EPS)
8.08
Revenue
24.85B
Net Profit
3.44B

About Safran SA

Sector
Tele & Telegraph Apparatus
Industry
Tele & Telegraph Apparatus
Headquarters
Paris, Paris, Fra
Founded
1924
Safran SA is listed in the Tele & Telegraph Apparatus sector of the Euronext with ticker SAF. The last closing price for Safran was 214.90 €. Over the last year, Safran shares have traded in a share price range of 156.68 € to 228.60 €.

Safran currently has 426,500,891 shares outstanding. The market capitalization of Safran is 91.66 € billion. Safran has a price to earnings ratio (PE ratio) of 26.20.

SAF Latest News

Italy Opposes Safran's Acquisition of Assets Related to Collins Aerospace Deal

By Giulia Petroni The Italian government is opposing Safran's proposed acquisition of Italian assets associated with Collins Aerospace's actuation and flight-control business, the French...

Safran Wins More Than $1.2 Billion in Contracts From Emirates Airline

By Mauro Orru France's Safran secured a series of contracts worth more than $1.2 billion from Emirates Airline to equip its new fleet of Airbus A350, Boeing 777X-9 and existing Boeing 777-300...

Safran Backs Guidance After Revenue Boost

By Mauro Orru Safran confirmed its forecasts for the year after revenue jumped in the third quarter as air traffic for narrowbody jets translated into strong demand for spare parts. The French...

Safran Wins Contract to Service Wizz Air Fleet

By Mauro Orru Safran secured a contract from central and eastern European low-cost airline Wizz Air Holdings to carry out maintenance, repair and overhaul operations on dozens of aircraft. The...

Safran Launches EUR1 Billion Buyback, Raises Guidance on Strong Demand

By Mauro Orru Safran is launching a share buyback program of up to 1 billion euros ($1.11 billion) and raised its guidance for the year after posting improved earnings and revenue in the first...

Correction to Safran Article

Safran said Friday that it plans to acquire the actuation and flight-control business from RTX's Collins Aerospace unit. "Safran to Buy Collins Aerospace's Flight-Control Business...

Safran to Buy Collins Aerospace's Flight-Control Business in $1.8 Billion Deal

By Adria Calatayud Safran said Friday that it plans to acquire the actuation and flight-control business from Raytheon Technologies' Collins Aerospace unit in a cash offer that values the...

Jet2 Orders engines from General Electric, Safran Venture

By Mauro Orru Leisure-travel group Jet2 ordered enough engines to power up to 71 Airbus A320neo and A321neo aircraft from CFM International, a joint venture of GE Aerospace and Safran Aircraft...

Safran in Talks Over Raytheon's Flight Control, Actuation Business

By Mauro Orru Safran said it is holding discussions with Raytheon Technologies over the potential acquisition of certain flight control and actuation activities. The French aerospace-industry...

Air Liquide in Talks With Safran for Sale of Oxygen, Nitrogen Aerospace Operations

By Pierre Bertrand Air Liquide said Thursday that it has entered into exclusive negotiations for the sale of its oxygen and nitrogen aerospace technology activities to Safran Aerosystems. The sale...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.60.761904761905210214.9209.1339452212.67499319DE
4-0.8-0.376647834275212.4216205.9537264210.62275931DE
1210.65.2736318408201228.6200.2589286214.49354352DE
269.64.75247524752202228.6184.7536275207.70554065DE
5251.732.3327079425159.9228.6156.68514511202.7254505DE
156103.2695.3110577811108.34228.687.85634163143.00688092DE
26074.454.2274052478137.2228.651.1779275123.44619005DE

SAF - Frequently Asked Questions (FAQ)

What is the current Safran share price?
The current share price of Safran is 211.60 €
How many Safran shares are in issue?
Safran has 426,500,891 shares in issue
What is the market cap of Safran?
The market capitalisation of Safran is EUR 91.66B
What is the 1 year trading range for Safran share price?
Safran has traded in the range of 156.68 € to 228.60 € during the past year
What is the PE ratio of Safran?
The price to earnings ratio of Safran is 26.2
What is the cash to sales ratio of Safran?
The cash to sales ratio of Safran is 3.63
What is the reporting currency for Safran?
Safran reports financial results in EUR
What is the latest annual turnover for Safran?
The latest annual turnover of Safran is EUR 24.85B
What is the latest annual profit for Safran?
The latest annual profit of Safran is EUR 3.44B
What is the registered address of Safran?
The registered address for Safran is 2 BOULEVARD DU GENERAL MARTIAL VALIN, PARIS, PARIS, 75724
What is the Safran website address?
The website address for Safran is www.safran-group.com
Which industry sector does Safran operate in?
Safran operates in the TELE & TELEGRAPH APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MLFXOFinaxo
0.895 €
(43.20%)
500
MLWEYWeya
0.0175 €
(34.62%)
5.1k
POXELPoxel
0.191 €
(33.57%)
4.22M
ALBIOBiosynex
2.50 €
(28.73%)
50.71k
SEQUASequana medical NV
3.02 €
(23.27%)
1.05M
BNBSTonner Drones
0.0005 €
(-50.00%)
524.03k
ALAGOEPango SA
0.127 €
(-41.20%)
11.94M
EIFDSTour Eiffel DS
0.0032 €
(-38.46%)
33.94k
FINMFinanciere Marjos
0.076 €
(-36.13%)
1.4k
ALALOAcheterLouerFR
0.20 €
(-33.33%)
90.63k
ATOAtos SE
0.0024 €
(-4.00%)
1.53B
BCPBanco Comercial Portugues SA
0.4623 €
(0.74%)
43.69M
ALTDTonner Drones
0.0118 €
(-7.81%)
27.49M
NEOENNeoen SA
39.74 €
(-0.15%)
21.76M
ALVERVergnet
0.002 €
(0.00%)
16.8M

Discussion

View Full Feed
axelvento axelvento 9 minutes ago
Q1 the first interim analysis of the vaccine’s efficacy is expected

Moderna’s mRNA-1647
Cytomegalovirus
MRNA
MightyX MightyX 12 minutes ago
Yet no one is innocent
TPTW
BIG D 4 BIG D 4 13 minutes ago
WOW !! HAPPY NEW YEAR TO ALL THE LONGS HERE !! I HAVE 2 NAYSAYERS ON IGNORE SO I NEVER READ THEIR BS !! GO SAVING GRACE-- JJ AND ALL THE NEW POSTERS WHO ARE POSITIVE !! .02 CENTS TO START THE RUN TO ONE DOLLAR IS WHERE WE SHOULD BE !! THIS STOCK IS SUCH A GREAT BUY HERE !! I AM LOADED WITH 32 MILLI
MJNA
MightyX MightyX 14 minutes ago
The judicial system legitimizes prosecution
TPTW
jondoeuk jondoeuk 15 minutes ago
A new paper. From it: 'BNT221 was well tolerated across both DLs, with no dose-limiting toxicities of grade 3 or higher attributed to the T cell product observed. Specifically, no cytokine release, immune effector cell-associated neurotoxicity or macrophage activation syndromes were reported. A dose
BNTX
benz280c benz280c 16 minutes ago
Nice to see you are bullish. This quote may round out your knowledge.
"It is worthy to note that a new CUSIP has been approved by the CUSIP Global Services (CGS).
Subsequently, we have submitted a corporation action with FINRA for a Company name change, Ticker Symbol Change and Cusip
GDVM
shajandr shajandr 17 minutes ago
Sorry to read that you're still feeling sick. I posted a week or two ago about 41 bunnies and also some cats and dogs that were rescued from a home in Delaware county, Iowa and that were transferred to the DBQ county animal shelter. I just spoke with DaSqu_w and she went to the animal shelter to see
Lakota-45 Lakota-45 18 minutes ago
Will do, but I doubt they will listen !!!

~ Lol !!!
IONI
boi568 boi568 19 minutes ago
Probably
AVXL
HokieHead HokieHead 21 minutes ago
Wrong..
TWOH
HokieHead HokieHead 21 minutes ago
Get your facts straight, the halt was in the Canadian side as they are reviewing all the disclosures submitted, there’s ZERO issues in the US, it’s a fully reporting SEC company.
TWOH
Lakota-45 Lakota-45 23 minutes ago
I agree with you 'farmI1234 !!!

I'm pretty sure most of the Savvy Investors, that have been paying attention,
have been loading the dips, and .0004's, for a while now.
I know I have, along with fishing down stream.

I doubt any Longs will get caught short,
WDLF
CaptHowdy CaptHowdy 24 minutes ago
RECOMMENDED.... nothing is offical yet, unnecessary twisting of facts to bolster your negative viewpoints. Thats news is two months old
GRLT
axelvento axelvento 25 minutes ago
Cancer vaccines: What’s ahead in 2025

The spotlight is on mRNA-4157 (V940)

https://gulfnews.com/special-reports/cancer-vaccines-whats-ahead-in-2025-1.500010233
MRNA
facts_matter14 facts_matter14 25 minutes ago
Does this sound like a company with 16 products and a 17th on the way?

https://investorshub.advfn.com/uimage/uploads/2024/12/24/mwowsIMG_6034.png








.
SRMX
HomerRomer HomerRomer 26 minutes ago
More testimony videos from trial participants like the Australian news reel of Ern Heaven would be amazing. I would think that most of the people involved 9 years ago in the earlier phase studies have passed on since the average life expectancy is normally between 3-11 years after being diagnosed w
AVXL
CaptHowdy CaptHowdy 27 minutes ago
That's how to make money on the OTC. 🤦🏻‍♂️ Anyone could do it; only if the effort spent discounting the new leadership in place along with the turn around story underway was used to turn a profit vs. using 9yr old DD to bad mouth new CEO.
GRLT
crescentmotor crescentmotor 27 minutes ago
I think that is a bad precedent to start.

100% on parading a handful of Blarcamesine patients at the JPM conference. I highly doubt AVXL would involve itself with anecdotal gimmicks where there is no way possible to extrapolate isolated successes to meaningful conclusions about broad
AVXL JPM
Steady_T Steady_T 30 minutes ago
MABS are the current standard of care, so Blarcamesine has to be better than the MABS, which is not saying much.

I suspect that if Blarcamesine was the equal of the MABS is would still be approved on safety and cost grounds.

As has been pointed out multiple times on the
AVXL
facts_matter14 facts_matter14 31 minutes ago
Looks like Baggy is worried about Maxine not showing up at CES this week…………….









.
SRMX
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 31 minutes ago
Anavex has delayed PD in order to wait out the development of a reliable biomarker, which has happened only during the past few months.

OK so we should see the test start this quarter then?
AVXL
Canna_Business Canna_Business 32 minutes ago
$FKINX $IONQ $FFALX $MRMD $RKLB $XOM $DUK $LNVGY $V $SOFI $BICEY $VOO $TEMWX
BICEY DUK FFALX
mrfence mrfence 32 minutes ago
Actually, these issues traded on the NYSE under conservatorship and the FHFA made a decision to voluntarily delist Fannie and Freddie from the NYSE. There's Companies in bankruptcy like Gamestop, GME, trading on Big Boards. Unfortunately, the ball's in Gooberment's as to when they see fit to up lis
GME
Canna_Business Canna_Business 32 minutes ago
$FKINX $IONQ $FFALX $MRMD $RKLB $XOM $DUK $LNVGY $V $SOFI $BICEY $VOO $TEMWX
BICEY DUK FFALX

Your Recent History

Delayed Upgrade Clock